SEC Form 4 · accession 0001209191-16-092030
Akebia Therapeutics, Inc. · AKBA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John P. Butler
Officer — CEO and President · Director
Period of report
Jan 15, 2016
Accepted (ET)
Jan 19, 2016 · 4:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001517022
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 15, 2016 | M | 25,000 | $0.47 | A | 225,673 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $0.47 | Jan 15, 2016 | M | 25,000 | D | — | Sep 16, 2023 | Common Stock | 25,000 | 407,000 | D |
Explanation of responses
- F1The total amount of beneficial securities owned includes 1,349 shares of stock purchased on June 30, 2015 at $8.74 per share and 974 shares of stock purchased on December 31, 2015 at $8.27 per share in connection with the Issuer's Employee Stock Purchase Plan.
- F2This transaction represents the acquisition of common stock as a result of the exercise and hold of derivative securities reported in Table II. This option was granted on September 16, 2013. Twenty-five percent vested on September 16, 2014 with the remaining seventy-five percent vesting in equal monthly installments thereafter until fully vested on September 1, 2017.